FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average	burden							
hours per response	e: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hochman David P (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol Orchestra BioMed Holdings, Inc. [OBIO] Date of Earliest Transaction (Month/Day/Year) 01/26/2023								ck all applica Director	able)		Person(s) to Issuer 10% Owner Other (specify below)		
C/O ORCHESTRA BIOMED HOLDINGS, INC. 150 UNION SQUARE DRIVE (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year) 01/30/2023								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
NEW HOPE PA 18938 (City) (State) (Zip)						Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa- Date (Month/D					action	2A. Deemed Execution Date,			3. 4. Secur Transaction Dispose Code (Instr. 5)		4. Securi	rities Acquired (A) or d Of (D) (Instr. 3, 4 a		5. Amoun Securities Beneficia Owned Fo	s Ily ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o (D)	Price	Reported Transacti (Instr. 3 a	ction(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,		5. Number of 6 Parinasaction ode (Instr. Securities (I			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title an of Securit Underlyin Derivative (Instr. 3 at			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		cpiration ate	Title	Amount or Number of Shares		Transactio (Instr. 4)	on(s)			
Nonstatutory Stock Option (Right to Buy) ⁽¹⁾	\$10	01/26/2023			A		300,181		(2)	08	8/17/2032	Common Stock	300,181	(3)	300,18	31	D		
Nonstatutory Stock Option (Right to Buy) ⁽¹⁾	\$10	01/26/2023			A		208,216		(4)	080	8/17/2032	Common Stock	208,216	(5)	208,21	.6	I	By the DPH 2008 Trust	
Nonstatutory Stock Option (Right to Buy) ⁽¹⁾	\$10	01/26/2023			A		116,250		(6)	01	./19/2033	Common Stock	116,250	(7)	116,25	50	D		

Explanation of Responses:

- 1. On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently (i) misstated the expiration dates of three classes of nonstatutory stock options ("NSOs") and (ii) misstated the vesting schedules for such NSOs. In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to (i) correct the incorrect expiration dates in Table II, Column 6 to August 17, 2032, August 17, 2032 and January 19, 2033, respectively, and (ii) correct the incorrect vesting schedules set forth in the footnotes corresponding to such NSOs, which are reproduced in this amendment with the correct vesting schedules; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing.
- 2. The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with September 30, 2022, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.
- 3. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 645,551 shares of Legacy Orchestra Common Stock for \$4.65 per share.
- 4. The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with September 30, 2022, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.
- 5. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 447,776 shares of Legacy Orchestra Common Stock for \$4.65 per share.
- 6. The NSOs vest over a three-year period as follows: (i) 44.4% of the underlying shares vested on the grant date and (ii) 55.6% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting with March 31, 2023, subject to the Reporting Person's continuous service through such dates. The grant date is January 20, 2023.
- 7. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 250,000 shares of Legacy Orchestra Common Stock for \$4.65 per share.

Chief Executive Officer and Chairperson

/s/ Matthew R. Schob, Attorney-in-Fact

05/19/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.